Johnson & Johnson Forecasts $23.6B Q1, Confronts Lilly’s Jaypirca Threat
Johnson & Johnson is projected to report $23.61 billion in Q1 revenue and $2.68 EPS on April 14, following a 17% year-to-date stock rally supported by a 21.61 P/E ratio and 0.59 debt-to-equity. J&J’s Imbruvica now faces heightened competition after Lilly’s Jaypirca Phase 3 trial showed superior progression-free survival, yet Johnson & Johnson still edges out Lilly in valuation strength and stock performance metrics.
1. Q1 Earnings Estimates and Valuation Metrics
Johnson & Johnson is set to release Q1 results on April 14, with projections of $23.61 billion in revenue and $2.68 earnings per share. The stock has rallied 17% year-to-date, trading at a price-to-earnings ratio of 21.61 while maintaining a debt-to-equity ratio of 0.59.
2. Financial Resilience and Dividend King Status
Annual revenue for Johnson & Johnson is expected to exceed $100 billion, reflecting robust growth despite patent expirations and ongoing legal challenges. The company has increased its dividend for over 50 consecutive years, reinforcing its reputation as a reliable income stock.
3. Competitive Pressure on Imbruvica
Eli Lilly’s Jaypirca achieved superior progression-free survival in the Phase 3 BRUIN CLL-322 trial, intensifying competitive pressure on J&J’s Imbruvica blood cancer therapy. Despite this challenge, Johnson & Johnson currently maintains stronger valuation and stock performance metrics than its rival.